Analysis Of The Immune Response Of NY-ESO-1 Specific T Cells In Cervical Cancer

Objective: To explore the specific T cell immune response of New York esophageal squamous cell carcinoma antigen 1(NY-ESO-1)in cancer-testis antigen(CTA)of cervical cancer(CC)patients and its correlation with clinical features,to provide a scientific basis for its preliminary application in immunotherapy of CC.Methods: A total of 31 newly diagnosed CC patients admitted to the Affiliated Tumor Hospital of Xinjiang Medical University from August 2018 to June 2019 were collected.The peripheral blood mononuclear cells(PBMCs)of CC patients were stimulated with synthetic NY-ESO-1antigen overlapping peptides,using cultured intracellular cytokine staining(Cultured ICS)technology to simultaneously detect the expression of 4 kinds of cytokines such as interferon-gamma(IFN-γ),interleukin-2(IL-2),interleukin-13(IL-13)and tumor necrosis factor-α(TNF-α)on T cells.Flow Jo10.6 flow cytometry software was used to analyze intracellular cytokine secretion and co-expression levels of peripheral blood T cell subsets in patients with CC,combined with clinical data to analyze its relationship with the clinical characteristics of CC patients.Results: 1)Peripheral blood of CC patients had an immune response rate of 67.4%(21/31)to NY-ESO-1 antigen peptide stimulation,of which CD4+ T cell immune response positive rate was 32.3%(10/31)and CD8+ T cell was 54.8%(17/31);2)CC NY-ESO-1 specific CD4+ T cell immune response frequency was significantly higher in the group with no history of miscarriage(63.6%)than in the group with a history of miscarriage(15.0%),and the difference between the two groups was statistically significant(P=0.018);CC NY-ESO-1 specific CD8+ T cell immune response frequency in the age≤52-year-old group(70.6%)was significantly higher than that in the > 52-year-old group(35.7%),and the statistical difference between the two groups was the critical value(P=0.052);3)Among patients with a positive NY-ESO-1specific CD4+ T cell immune response,50%of patients secreted multiple cytokines,and patients who secreted a single cytokine had a worse prognosis than patients who secreted multiple cytokines.The 2-year OS rate between the two groups was 40% vs 100%(P=0.049).Conclusion: NY-ESO-1 antigen polypeptide can produce specific T cell immune responses in the peripheral blood of CC patients,providing clues for CC immunotherapy research.